An invention born at RMIT University will go on sale for the first time ever in July, following regulatory approval from the US Food and Drug Administration for an ingestible capsule that can help diagnose gut disorders. According to a statement from RMIT on Monday, Atmo Biosciences’ device has moved “from concept to clinical reality”…
An ingestible capsule used to monitor gut health markers has taken another small step towards commercialisation, with RMIT University transferring IP ownership to Atmo Biosciences. Digital health business Atmo Biosciences is commercialising a capsule that it says “measures gases as it travels through the gastrointestinal tract and transmits the data wirelessly” and which was first…
Breakthrough Victoria has announced an investment in Atmo Biosciences, a medical technology company that has developed capsules that are swallowed and electronically diagnose gastrointestinal disorders. Breakthrough Victoria — an independent company set up in 2021 to manage the state government’s $2 billion Breakthrough Victoria Fund — did not disclose the size of the investment. In…